Cellectis bioresearch Inc. wins a $6.9 million contract with The National Institutes of Health on iPS cells
Published on October 23, 2012
Cambridge, Massachusetts (United States) October 23rd 2012 - Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), announces that it has been awarded a second contract to provide services to the National Institutes of Health (NIH) and certain other government agencies.
Cellectis bioresearch Inc. has been awarded a second contract to provide services to the National Institutes of Health (NIH) and several government agencies
This multiple award, indefinite delivery/indefinite quantity (IDIQ) contract, has a maximum order limit of $6,9 million over a period of three years.
Under the terms of the contract, the scope of work includes generation of induced pluripotent stem (iPS) cell lines of research grade and differentiation of iPS cells toward specific tissue cell type for research use.
This second major contract following the one announced October 16th further reaffirms Cellectis Group’s expertise. We saw since 2010 the huge potential of investment in license agreements for Professor Yamanaka’s iPS patents. Furthermore Professor Shinya Yamanaka has been awarded the 2012 Nobel Prize in Medicine.
“The second contract won through a NIH call for tenders dedicates our company as a leading competitor and an expert in the field in the United States” said Marc Le Bozec, CEO of Cellectis bioresearch.
André Choulika, CEO of Cellectis declared: "this contract award granted by the most prestigious US research organization the NIH is a great recognition for Cellectis Group as the world's largest biotech for the design, manufacture and engineer of human cells and cell lines for the drug discovery and development.”